Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics的第一季度現金和現金等價物爲3,400萬美元，根據吉利德協議於2024年4月收到的3000萬美元預付款，以及2024年4月的私募總收益約爲1460萬美元，預計將爲2025年第二季度提供現金流道
Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Xilio Therapeutics的第一季度現金和現金等價物爲3,400萬美元，根據吉利德協議於2024年4月收到的3000萬美元預付款，以及2024年4月的私募總收益約爲1460萬美元，預計將爲2025年第二季度提供現金流道
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。